Published in Bull Cancer on February 01, 2011
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med (2002) 19.60
Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis (2008) 16.51
Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis (2002) 6.13
Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis (2007) 5.15
Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis (2006) 4.88
Sequence elements outside the hammerhead ribozyme catalytic core enable intracellular activity. Nat Struct Biol (2003) 4.64
Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis (2006) 4.42
Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol (2009) 3.38
Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis (2008) 3.18
Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol (2009) 2.68
Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis (2008) 2.55
Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis (2006) 2.45
Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol (2002) 2.31
Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med (2015) 2.18
Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood (2005) 1.99
Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). Haematologica (2012) 1.80
Caspofungin: the first representative of a new antifungal class. J Antimicrob Chemother (2003) 1.71
Association of mannose-binding lectin deficiency with acute invasive aspergillosis in immunocompromised patients. Clin Infect Dis (2009) 1.55
Constitutive activation of the androgen receptor by a point mutation in the hinge region: a new mechanism for androgen-independent growth in prostate cancer. Int J Cancer (2004) 1.54
A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis (2009) 1.54
Changes in causes of death over time after treatment for invasive aspergillosis. Cancer (2008) 1.46
Risk factors for Gram-negative bacterial infections in febrile neutropenia. Haematologica (2005) 1.44
Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients. J Antimicrob Chemother (2011) 1.39
Identification of novel truncated androgen receptor (AR) mutants including unreported pre-mRNA splicing variants in the 22Rv1 hormone-refractory prostate cancer (PCa) cell line. Hum Mutat (2010) 1.37
International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole. Antimicrob Agents Chemother (2010) 1.35
Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood (2003) 1.34
Function of Ikaros as a tumor suppressor in B cell acute lymphoblastic leukemia. Am J Blood Res (2013) 1.33
Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA. Haematologica (2011) 1.31
Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer (2006) 1.30
Functional hammerhead ribozymes naturally encoded in the genome of Arabidopsis thaliana. Plant Cell (2005) 1.26
Proteomic analysis of malignant lymphocyte membrane microparticles using double ionization coverage optimization. Proteomics (2006) 1.24
Early serum galactomannan trend as a predictor of outcome of invasive aspergillosis. J Clin Microbiol (2012) 1.23
Prognostic factors for death due to invasive aspergillosis after hematopoietic stem cell transplantation: a 1-year retrospective study of consecutive patients at French transplantation centers. Clin Infect Dis (2006) 1.22
A splicing variant of the androgen receptor detected in a metastatic prostate cancer exhibits exclusively cytoplasmic actions. Endocrinology (2007) 1.21
Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial). Cancer (2007) 1.19
A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther (2003) 1.19
Geriatric oncology, general practitioners and specialists: current opinions and unmet needs. Crit Rev Oncol Hematol (2009) 1.18
Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. Clin Infect Dis (2007) 1.17
The enzymatic basis of drug-drug interactions with systemic triazole antifungals. Clin Pharmacokinet (2008) 1.16
Voriconazole for invasive bone aspergillosis: a worldwide experience of 20 cases. Clin Infect Dis (2005) 1.15
Signal transduction pathways of taxanes-induced apoptosis. Curr Med Chem Anticancer Agents (2003) 1.14
Disseminated Trichosporon mycotoxinivorans, Aspergillus fumigatus, and Scedosporium apiospermum coinfection after lung and liver transplantation in a cystic fibrosis patient. J Clin Microbiol (2012) 1.11
Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas. Eur J Cancer (2012) 1.11
Aprepitant for erlotinib-induced pruritus. N Engl J Med (2010) 1.11
Clinical pharmacokinetics of voriconazole. Int J Antimicrob Agents (2006) 1.10
Role of cationic channel TRPV2 in promoting prostate cancer migration and progression to androgen resistance. Cancer Res (2010) 1.09
Severe intoxication with methotrexate possibly associated with concomitant use of proton pump inhibitors. Anticancer Res (2010) 1.05
Successful outcome of treatment of a disseminated infection due to Fusarium dimerum in a leukemia patient. J Clin Microbiol (2002) 1.03
Epidemiology and risk factors for gram-positive coccal infections in neutropenia: toward a more targeted antibiotic strategy. Clin Infect Dis (2003) 1.00
Drug-drug interactions of triazole antifungal agents in multimorbid patients and implications for patient care. Curr Drug Metab (2009) 0.99
Unexpected paracrine action of prostate cancer cells harboring a new class of androgen receptor mutation--a new paradigm for cooperation among prostate tumor cells. Int J Cancer (2007) 0.98
HDAC inhibitors induce apoptosis in glucocorticoid-resistant acute lymphatic leukemia cells despite a switch from the extrinsic to the intrinsic death pathway. Int J Biochem Cell Biol (2007) 0.98
Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome. Clin Infect Dis (2005) 0.97
Saccharomyces cerevisiae fungemia: an adverse effect of Saccharomyces boulardii probiotic administration. Clin Infect Dis (2005) 0.97
Forum report: issues in clinical trials of empirical antifungal therapy in treating febrile neutropenic patients. Clin Infect Dis (2003) 0.96
Early proinflammatory cytokines and C‐reactive protein trends as predictors of outcome in invasive Aspergillosis. J Infect Dis (2010) 0.95
Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial. Br J Haematol (2012) 0.95
Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries. Haematologica (2013) 0.93
Specific properties of a C-terminal truncated androgen receptor detected in hormone refractory prostate cancer. Adv Exp Med Biol (2008) 0.93
Breakthrough invasive mould infections in patients treated with caspofungin. J Infect (2011) 0.93
Diffuse primary angiosarcoma of the pleura: a case report and review of the literature. Sarcoma (2004) 0.92
Potential clinical impact of medication discrepancies at hospital admission. Eur J Intern Med (2013) 0.92
Constitutively active androgen receptor variants upregulate expression of mesenchymal markers in prostate cancer cells. PLoS One (2013) 0.91
Adriamycin, cisplatin, ifosfamide and paclitaxel combination as front-line chemotherapy for locally advanced and metastatic angiosarcoma. Analysis of three case reports and review of the literature. Anticancer Res (2008) 0.88
A multicentre pharmacoepidemiological study of therapeutic practices in invasive fungal infections in France during 1998-1999. J Antimicrob Chemother (2004) 0.88
A V530I Mutation in c-KIT Exon 10 Is Associated to Imatinib Response in Extraabdominal Aggressive Fibromatosis. Sarcoma (2010) 0.87
A unique proteomic profile on surface IgM ligation in unmutated chronic lymphocytic leukemia. Blood (2011) 0.87
Off-label use of oxaliplatin in patients with metastatic breast cancer. Anticancer Res (2011) 0.86
Polycythemia vera transforming to acute myeloid leukemia and complex abnormalities including 9p homogeneously staining region with amplification of MLLT3, JMJD2C, JAK2, and SMARCA2. Cancer Genet Cytogenet (2008) 0.86
Invasive infections due to Candida norvegensis and Candida inconspicua: report of 12 cases and review of the literature. Med Mycol (2013) 0.85
Gastrointestinal stromal tumor in an XYY/XY male. Cancer Genet Cytogenet (2002) 0.85
Efficacy outcomes in a randomised trial of liposomal amphotericin B based on revised EORTC/MSG 2008 definitions of invasive mould disease. Mycoses (2010) 0.85
Proteomic analysis of malignant B-cell derived microparticles reveals CD148 as a potentially useful antigenic biomarker for mantle cell lymphoma diagnosis. J Proteome Res (2009) 0.85
A yeast-based functional assay for the detection of the mutant androgen receptor in prostate cancer. Eur J Endocrinol (2003) 0.85
Successful treatment of a granulocytic sarcoma of the uterine cervix in complete remission at six-year follow-up. J Oncol (2010) 0.84
Adherence to recommendations for the use of antifungal agents in a tertiary care hospital. J Antimicrob Chemother (2012) 0.84
Computer tomography in pulmonary invasive aspergillosis in hematological patients with neutropenia: an useful tool for diagnosis and assessment of outcome in clinical trials. Eur J Radiol (2009) 0.83
Liposomal nystatin in patients with invasive aspergillosis refractory to or intolerant of amphotericin B. Antimicrob Agents Chemother (2004) 0.83
Systematic review and mixed treatment comparison of randomized evidence for empirical, pre-emptive and directed treatment strategies for invasive mould disease. J Antimicrob Chemother (2011) 0.83
Paralytic ileus possibly associated with interaction between ritonavir/lopinavir and vincristine. Pharm World Sci (2009) 0.83
Risk of hormone escape in a human prostate cancer model depends on therapy modalities and can be reduced by tyrosine kinase inhibitors. PLoS One (2012) 0.83
Long-term survival in post-transplant lymphoproliferative disorders with a dose-adjusted ACVBP regimen. Br J Haematol (2006) 0.82
Lessons from a case of oromandibular mucormycosis treated with surgery and a combination of amphotericin B lipid formulation plus caspofungin. Acta Haematol (2010) 0.82
New strategies for medical management of castration-resistant prostate cancer. Oncology (2011) 0.82
An elevated pro-inflammatory cytokine response is linked to development of amphotericin B-induced nephrotoxicity. J Antimicrob Chemother (2013) 0.81
Effect of pO2 on antitumor drug cytotoxicity on MDR and non-MDR variants selected from the LoVo metastatic colon carcinoma cell line. Anticancer Res (2008) 0.81
Cola beverage and delayed elimination of methotrexate. Br J Clin Pharmacol (2010) 0.81